Friday, July 10, 2026

Drug profile · INN

voretigene neparvovec

voretigene neparvovec (LUXTURNA) is a retinoid isomerohydrolase exogenous gene.

EMA: approved Sensory organs (S01) S01XA27
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — voretigene neparvovec
Class
Sensory organs (S01)
Route
Patents
0
Programs
0
Data quality
0.83

Quick answer

voretigene neparvovec (LUXTURNA) is a retinoid isomerohydrolase exogenous gene.

Key facts

INN voretigene neparvovec
Brand LUXTURNA
Mechanism Retinoid isomerohydrolase exogenous gene
Target Retinoid isomerohydrolase
Therapeutic class Sensory organs (S01)
ATC code S01XA27

Mechanism of action

Retinoid isomerohydrolase exogenous gene

Primary target: Retinoid isomerohydrolase

Approval history

Authority Status Date
EMA approved

Related & competitor drugs

  1. aflibercept Sensory organs (S01)
  2. atropine sulfate Sensory organs (S01)
  3. bimatoprost Sensory organs (S01)
  4. atropine Sensory organs (S01)
  5. brinzolamide Sensory organs (S01)
  6. latanoprost Sensory organs (S01)

Frequently asked questions

What is voretigene neparvovec?

voretigene neparvovec (LUXTURNA) is a retinoid isomerohydrolase exogenous gene.

What is the brand name for voretigene neparvovec?

LUXTURNA is a marketed brand name for voretigene neparvovec. Check FDA Drugs@FDA for the current US label holder and prescribing information.